A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

200150 citationsJournal Article

Authors

Good health and well-being

Published in: Vaccine

Volume 19, Issue 23-24, pp. 3033-3042

Field-Weighted Citation Impact: 2.05